Estée Lauder
No proof required
Up to $5,000
Claims opening soon
V
Vyera Pharmaceuticals
Vyera Pharmaceuticals agreed to pay up to $28 million to third-party payors who reimbursed Daraprim between 2015 and 2022.
ClosedUnited States-wideClaim status: Closed on June 1, 2022Payout: VariesNo longer claimable
About this settlement
Settlement for third-party payors who reimbursed Daraprim, addressing alleged anti-competitive practices and price inflation.
This class action settlement resolves claims that Vyera Pharmaceuticals suppressed generic alternatives and raised prices for the malaria drug Daraprim. Eligible third-party payors who reimbursed Daraprim between 2015 and 2022 may receive compensation based on submitted documentation.
Who qualifies
- Third-party payors who paid or reimbursed Daraprim between August 7, 2015 and January 28, 2022.
- Includes health insurance companies, benefit plans, self-insured employers, and similar entities.
Varies
Claim status: Closed on June 1, 2022
Silk and Great Value
Proof required
Up to $300,000
96 days left
Audible
No proof required
Compensation pending
Claims opening soon
Government of Canada
Proof required
Up to $200,000
746 days left
Meta (Facebook)
No proof required
Up to $90
Claims opening soon
Ticketmaster
No proof required
Compensation pending
Claims opening soon